nach oben

Erschienen in:

26.10.2021 | Morbus Crohn | Zertifizierte Fortbildung

Chronisch entzündliche Darmerkrankungen

Therapie-Update Morbus Crohn 2021

verfasst von: Prof. Dr. med. Klaus Herrlinger, Chefarzt, Prof. Dr. med. Eduard F. Stange

Erschienen in: Gastro-News | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Auszug

Die aktuellen Leitlinien der DGVS und der ECCO liefern die Grundlage für evidenzbasierte Therapieentscheidungen bei Morbus Crohn. In diesem Therapie-Update wird auf dieser Basis ein anwendungsorientierter Therapiealgorithmus vorgestellt und es werden die Therapieergebnisse der konventionellen und neueren Medikamente, auch bezüglich mukosaler Heilung und Krankheitsprogression, kritisch diskutiert. …

Wehkamp J, Stange EF. An Update Review on the Paneth Cell as Key to Ileal Crohn's Disease. Front Immunol 2020;11:646

Stange EF, Schröder BO. Microbiota and mucosal defense in IBD: an update. Expert Rev Gastroenterol Hepatol 2019;13(10):963-76

Klag, T, Wehkamp J, Stange E. Wirkmechanismen und Wirkung von Biologika und JAK-Inhibitoren bei CED. Gastro-News 2019;6:26-37

Gomollón F et al. 3^rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohn's Colitis 2017:3-25

Feuerstein JD, Ho EY, Shmidt E et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease Gastroenterology 2021;160:2496-508

Modigliani R, Gendre JP, Galmiche JP et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996;110(3):688-93

Chande N, Townsend CM, Parker CE et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2016;10:CD000545

Chande N et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2015;10:CD000067

Candy S et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37(5):674-8

10.

Colombel JF et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95

11.

Hu A et al. Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab. Clin Gastroenterol Hepatol 2021;19(7):1366-76.e2

12.

Singh S et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther 2018; 48(4):394-409

13.

Herrlinger KR, Stange EF. 25 years of biologicals in IBD: what´s all the hype about? J Internal Medicine. DOI: 10.1111/joim.13345

14.

Faleck DM, Shmidt E, Huang R et al. Effect of concomitant therapy with steroids and tumor necrosis factor antagonists for induction of remission in patients with Crohn's disease: a systematic review and pooled meta-analysis. Clin Gastroenterol Hepatol 2021;19(2):238-45.e4

15.

Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10(10):2132

16.

Sudheer K et al. Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients w ith stricturing Crohn's disease. Scientific Reports 2021;11:11704

17.

Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol 2021;6(7):589-95

18.

Targownik LE et al. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. J Crohns Colitis 2020;14(10):1354-63

19.

Raine T, Verstockt B, Kopylov U, et al. ECCO topical review: Refractory IBD. J Crohn´s Colitis Doi: 10.1093/ecco-jcc/jjab112

20.

Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease-based on results from a regional patient group from the county of Copenhagen. Gut 1985;26:146-50

21.

D'Haens G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-67

22.

Safroneeva E et al. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Aliment Pharmacol Ther 2015;42(8):977-89

23.

Stange EF, Wehkamp J. Recent advances in understanding and managing Crohn's disease. F1000Res. 2016. doi: 10.12688/f1000research.9890.1.

24.

Hanauer SB et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9

25.

Blesl A, Binder L, Högenauer C. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study Aliment Pharmacol Ther 2021;00:1-11

26.

Zeze K, Hirano A, Torisu T. Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn's Disease: A Retrospective Study Digestive Diseases and Sciences https://doi.org/10.1007/s10620-020-06600-z

27.

Yang Z et al. A network meta-analysis on the efficacy of 5-aminosalicylates, immunomodulators and biologics for the prevention of postoperative recurrence in Crohn's disease Int J Surg 2014;12(5):516-22

28.

Gjuladin-Hellon T, Iheozor-Ejiofor Z, Gordon M, Akobeng AK. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2019; 8(8):CD010233

29.

Stange E. Exitstrategien aus der Immuntherapie - Ausstieg ist oft riskant. Gastro-News 2020;37-41

30.

Lee MJ et al. Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis.Clin Gastroenterol Hepatol 2018;16(12):1879-92

31.

Turner D et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals For Treat to Target Strategies in IBD. Gastroenterology 2021;160(5):1570-83

32.

Geyl S, Guillo L, Laurent V, et al. Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. Lancet Gastroenterol Hepatol 2021;6(8):659-67

33.

Stange, E. Tiefe Remission und Krankheitsprogression. Gastro-News 2020;7:34-35

34.

Ostaff MJ et al. Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med 2013;5(10):1465-83

35.

Silverberg MS et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A:5A-36A

36.

Wolters FL, Russel MG, Sijbrandij J, et al. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl 2006;(243):46-54

37.

Ditrich F et al. Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort. Therap Adv Gastroenterol 2020;13:1-11

38.

Jeuring SF et al. Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort. Am J Gastroenterol 2017;112(2):325-36

39.

Murthy SK et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut 2020;69(2):274-82

40.

Khanna R et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 2015;386:1825-34

41.

Guberna L et al. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132

42.

Watterdal Syversen S et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial JAMA 2021;325(17):1744-54

43.

Péntek Met al. Access to biologicals in Crohn's disease in ten European countries. World J Gastroenterol 2017;23(34):6294-305

44.

Atreya R, Neurath MF and Siegmund B. Personalizing treatment IBD: Hype or reality in 2020? Can we predict response to Anti-TNF? Front Med (Lausanne) 2020;7:517

45.

Beaugerie JL, Rahier JL, Kirchgesner J, et al. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020; 18(6):1324-35.e2

46.

Beaugerie JL, Kirchgesner J. Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 2019;17:370-9

47.

Click B, Regueiro M. Managing Risks with Biologics. Current Gastroenterology Reports (2019) 21: 1 https://doi.org/10.1007/s11894-019-0669-6

48.

Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134(4):929-36

49.

Truong A et al. Anti-Tumour Necrosis Factor Therapy is Associated with De novo Crohn's Disease After Ileal Pouch-Anal Anastomosis. Colorectal Dis 2021. doi: 10.1111/codi.15772.

50.

Bohm M, Xu R, Zhang Y et al. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Aliment Pharmacol Ther 2020; 52:669-681

51.

van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 2014 Jan;63(1):72-9.

52.

Linschoten RCA, Visser E, Niehot CD, et al. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther 2021. doi: 10.1111/apt.16445.

Titel: Chronisch entzündliche Darmerkrankungen
Therapie-Update Morbus Crohn 2021
verfasst von: Prof. Dr. med. Klaus Herrlinger, Chefarzt
Prof. Dr. med. Eduard F. Stange
Publikationsdatum: 26.10.2021
Verlag: Springer Medizin
Schlagwörter: Morbus Crohn
Azathioprin
Infliximab
Ustekinumab
Budesonid
Azathioprin
Bauchschmerzen
Erschienen in: Gastro-News / Ausgabe 5/2021
Print ISSN: 1869-1005
Elektronische ISSN: 2520-8667
DOI: https://doi.org/10.1007/s15036-021-2391-0

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Therapieregime zur H.-pylori-Eradikation

Therapieoption der konventionell nicht beherrschbaren Varizenblutung bei Zirrhose

Neue, natürliche Therapie bei Sodbrennen

Anti-PD-1-Erhaltungstherapie bei Ösophagus- und AEG-Karzinomen

Obeticholsäure in der Zweitlinie mit langanhaltendem Ansprechen

Morbus Crohn oder Darm-Tuberkulose?

Magen-Darm-Erkrankungen in der Hausarztpraxis